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The administration of the ryanodine receptor (RyR) agonist 4-Cmc (0.003–9 nmol per mouse intracerebroventricularly
[i.c.v.]) ameliorated memory functions, whereas the RyR antagonist ryanodine (0.0001–1 nmol per mouse i.c.v.)
induced amnesia in the mouse passive avoidance test. The role of the type 1, 2, and 3 RyR isoforms in memory
processes was then evaluated by inhibiting the expression of the three RyR proteins in the mouse brain. A selective
knockdown of the RyR isoforms was obtained by the i.c.v. administration of antisense oligonucleotides (aODNs)
complementary to the sequence of RyR1, RyR2 and RyR3 proteins, as demonstrated by immunoblotting experiments.
RyR1 (5–9 nmol per mouse i.c.v.) knockdown mice did not show any memory dysfunction. Conversely, RyR2
(1–7 nmol per mouse i.c.v.) and RyR3 (1–7 nmol per mouse i.c.v.) knockdown animals showed an impairment of
memory processes. This detrimental effect was temporary and reversible, disappearing 7 d after the end of the
aODN treatment. At the highest effective doses, none of the compounds used impaired motor coordination, as
revealed by the rota rod test, nor modified spontaneous mobility and inspection activity, as revealed by the
hole-board test. In conclusion, the lack of any involvement of cerebral RyR1 was demonstrated. These findings also
showed the involvement of type 2 and type 3 RyR in the modulation of memory functions identifying these cerebral
RyR isoforms as critical targets underlying memory processes.
An increase in cytoplasmic Ca2+ in hippocampal neurons plays
an important role in the regulation of neuronal processes, includ-
ing synaptic transmission and synaptic plasticity such as long-
term potentiation (LTP) and long-term depression (Nishiyama et
al. 2000; Balkowiec and Katz 2002). It has also been proposed
that altered Ca2+ regulation might play a role in brain aging and
Alzheimer’s disease (Gibson and Peterson 1987; Landfield 1987;
Khachaturian 1989; Disterhoft et al. 1994). In brain neurons
from aging rodents and rabbits, as compared with neurons from
younger animals, Ca2+ influx associated with action potentials
induces a larger Ca2+-dependent afterhyperpolarization (AHP)
(Landfield and Pitler 1984; Moyer et al. 1992; Potier et al. 1992;
Disterhoft et al. 2004; Stutzmann et al. 2006) and impairs short-
term synaptic plasticity (Landfield et al. 1986; Thibault et al.
2001). Furthermore, these findings have been reinforced by stud-
ies showing that pharmacologically isolated Ca2+ action poten-
tials (Pitler and Landfield 1990; Disterhoft et al. 1996), whole-cell
Ca2+ currents (Campbell et al. 1996), and Ca2+ transients during
repetitive spike trains also are larger in hippocampal neurons
from aged animals (Thibault et al. 2001; Hemond and Jaffe 2005).
An apparent excess Ca2+ influx via L-type voltage-gated Ca2+
channels (L-VGCC) appears to be involved in this Ca2+ dysregu-
lation (Landfield 1996; Thibault et al. 1998).
In addition to the accumulating evidence of increased Ca2+
influx through L-VGCCs, there is also recent evidence that al-
tered function of intracellular organelles might play a critical role
in Ca2+ regulation during aging or Alzheimer’s disease (Toescu
and Verkhratsky 2003). In particular, changes in intracellular
Ca2+ release from the endoplasmic reticulum appear likely to
contribute to brain Ca2+ dyshomeostasis and have been associ-
ated with changes in [Ca2+]i.
During neuronal activation, one important feature of Ca2+
signaling is the release of intracellular Ca2+ stores as a conse-
quence of Ca2+ influx through voltage- or ligand-gated Ca2+
channels, the Ca2+-induced Ca2+ release (CICR) (Tully and Treist-
man 2004). The mechanism through which CICR occurs is by
activation of ryanodine receptors (RyR), one of the two Ca2+ re-
lease channels found on the endoplasmic reticulum.
RyRs are widely expressed in mammalian brain (Giannini et
al. 1995), where they play a central role in the regulation of
intracellular calcium homeostasis (Simpson et al. 1995). RyRs
regulate vital brain functions, including protein synthesis (Pas-
chen et al. 1996), neurotransmitter release (Mothet et al. 1998;
He et al. 2000), action potential hyperpolarization (Kawai and
Watanabe 1989), and axonal retrograde transport (Breuer et al.
1992).
These receptors localize in the endoplasmic reticulum in the
cell soma, dendrites, dendritic spines, and synaptic terminals
(Sharp et al. 1993). Three main isoforms of the receptor (RyR1,
RyR2, and RyR3) are present in brain, the RyR2 being predomi-
nant (Zalk et al. 2007). To date little is known on the role of the
three neuronal RyR isoforms from behavioral studies. The aim of
the present study was to investigate the involvement of RyR1,
RyR2, and RyR3 in the intracellular mechanism involved in
memory processes in a mouse passive avoidance task. To this
purpose, we selectively inhibited the expression of each RyR sub-
type by using antisense oligonucleotides.
Results
Effect of RyR pharmacological modulators on memory
processes
The RyR agonist 4-chloro-m-cresol (4-Cmc; 0.003–9 nmol per
mouse intracerebroventricularly [i.c.v.], administered 30 min be-
fore the training session) increased the latency to enter the dark
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compartment in the retention session of the mouse passive
avoidance test. The ANOVA on the retention session latencies
revealed a significant group effect (F(8,162) = 4.506; P < 0.0001).
Bonferroni/Dunn multiple comparison analysis showed that
mice receiving either 0.03 (P < 0.05) or 0.3 nmol (P < 0.05) per
mouse i.c.v. of 4-Cmc spent significantly more time to enter the
dark compartment than controls. (Fig. 1A). In these experimental
conditions, diphenhydramine (20 mg/kg intraperitoneally [i.p.])
and clonidine (0.125 mg/kg i.p.), used as reference drugs, pro-
duced a statistically significant amnesic effect (P < 0.05 vs. con-
trol group) (Fig. 1A). Time course experiments on 4-Cmc (0.03
nmol per mouse) revealed an overall significant difference be-
tween groups (F(4,75) = 4.286; P < 0.001). Bonferroni/Dunn mul-
tiple comparison analysis showed that a significant 4-Cmc-
induced ameliorating effect on memory functions was obtained
when administered 30 min before the training session (P < 0.05)
(Fig. 1B).
The RyR antagonist ryanodine (0.01–1 nmol per mouse
i.c.v.) was devoid of any effect when injected 15 min before the
training session, as illustrated in Figure 2A. When administered
immediately after the training session, an amnesic effect was ob-
tained. The ANOVA on the retention session latencies revealed a
significant group effect (F(7,135) = 3.954; P < 0.001). Bonferroni/
Dunn multiple comparison analysis showed that mice receiving
0.01 (P < 0.05), 0.1 (P < 0.05) or 0.6 nmol (P < 0.05) per mouse
i.c.v. of ryanodine spent significantly less time to enter the dark
compartment than controls. The intensity of the amnesia ob-
tained was comparable to that induced by clonidine (0.125 mg/
kg i.p.) and diphenhydramine (20 mg/kg i.p.) (Fig. 2B).
The amnesia induced by ryanodine (0.1 nmol per mouse
i.c.v. injected immediately after the training session) was prevented
by 4-Cmc (injected 30 min before the training session) coadminis-
tration (F(5,109) = 3.941; P < 0.01). Bonferroni/Dunn multiple
comparison analysis confirmed the RyR-mediated mechanism of
ryanodine-induced amnesia. Indeed, the detrimental effect of
ryanodine was prevented by pretreatment with 4-Cmc at the
dose of 9 nmol per mouse (P < 0.05) (Fig. 3). Both 4-Cmc con-
centrations used were ineffective when injected alone (Fig. 3).
4-Cmc and ryanodine did not alter the latency to enter the
dark compartment in the training session in comparison with
control groups as shown in Figures 1, 2, and 3.
Role of type 1, 2, and 3 RyR in memory processes
Pretreatment with an aODN against type 1 RyR (5–9 nnmol per
mouse i.c.v.) did not modify the entrance latency in the dark
Figure 1. (A) Dose-response curve of 4-Cmc in the mouse passive
avoidance test. 4-Cmc (0.003–9 nmol per mouse i.c.v.) was administered
30 min before the training session. Data are expressed as mean  SEM;
*P < 0.05 in comparison with vehicle-treated mice. (Vehicle) Ethanol
0.5%; (clon) clonidine 0.125 mg/kg i.p.; (diph) diphenhydramine 20
mg/kg i.p. (B) Time-course curve of 4-Cmc in the mouse passive avoid-
ance test. 4-Cmc (0.03 nmol per mouse i.c.v.) was administered 15, 30,
or 60 min before and immediately after the training session. Data are
expressed as mean  SEM; *P < 0.05 in comparison with vehicle-treated
mice. (Vehicle) Ethanol 0.5%
Figure 2. (A) Lack of effect of ryanodine in the mouse passive avoid-
ance test. Ryanodine (0.01–1 nmol per mouse i.c.v.) was administered 15
min before the training session. Data are expressed as mean  SEM;
*P < 0.05 in comparison with saline-treated mice; (clon) clonidine 0.125
mg/kg i.p.; (diph) diphenhydramine 20 mg/kg i.p. (B) Dose-response
curve of the amnesic effect of ryanodine in the mouse passive avoidance
test. Ryanodine (0.0001–1 nmol per mouse i.c.v.) was administered im-
mediately after the training session. Data are expressed as mean  SEM;
*P < 0.05 in comparison with vehicle-treated mice; (clon) clonidine 0.125
mg/kg i.p.; (diph) diphenhydramine 20 mg/kg i.p.
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compartment in comparison with dODN treated mice. In the
same experimental conditions clonidine (0.125 mg/kg i.p.) was
able to induce amnesia (F(4,85) = 3.908; P < 0.01) (Fig. 4A).
Knockdown of the type 2 RyR produced a detrimental effect
on memory processes. The ANOVA on the retention session la-
tencies revealed a significant group effect (F(4,80) = 5.141;
P < 0.001). Bonferroni/Dunn multiple comparison analysis
showed that mice receiving 7 nmol per mouse i.c.v. showed a
significant lower latency to enter the dark compartment in com-
parison with dODN group (P < 0.05). The reduction of the en-
trance latency in the retention session was of intensity comparable
to that produced by clonidine (Fig. 4B). Similarly, the knock-
down of the type 3 RyR produced a detrimental effect on memory
functions (F(4,83) = 5.468; P < 0.001) reaching the statistical sig-
nificance at 7 nmol per mouse i.c.v. (Bonferroni/Dunn multiple
comparison analysis: P < 0.05), as illustrated in Figure 4C.
Anti-RyR1, anti-RyR2, and anti-RyR3 did not modify the
mouse entrance latency in the training session in comparison
with the control groups (Fig. 4).
Effect of aODNs on RyR1, RyR2, and RyR3 protein
levels
Mice were treated with the aODNs on day 1, 2, and 3. On day 4,
18 h after the last i.c.v. injection, mice were killed, and the cortex
and hippocampus were dissected and examined for the protein
levels of RyR1, RyR2, and RyR3 in comparison with mice treated
with dODN using specific antisera developed against each RyR
isoform. Figure 5A shows a representative immunoblot where
three distinct prominent protein bands of ∼500 kDa were ob-
served, which display a tissue specificity of expression. The anti-
RyR1 antiserum selectivity was demonstrated by a specific inter-
action with RyR1 proteins present in the sarcoplasmic reticulum
of skeletal muscle whereas the anti-RyR2 antiserum recognized
the RyR2 proteins in cardiac muscle. RyR2 and RyR3 proteins
were detected in all brain areas investigated. Conversely, RyR1
isoform was not detected in mouse cortex (Fig. 5A).
Densitometric analysis of all samples revealed a statistically
significant reduction of the expression of RyR1 (P < 0.05,
Student’s t-test), RyR2 (F(2,18) = 4.562; P < 0.05) and RyR3
(F(2,18) = 4.186; P < 0.05) after aODN treatment at the highest
concentration used (anti-RyR1 9 nmol i.c.v.; anti-RyR2 7 nmol
i.c.v.; anti-RyR3 7 nmol i.c.v.) in comparison with mice treated
with the corresponding dODN (Fig. 6B). Bonferroni/Dunn mul-
tiple comparison analysis confirmed that every aODN treatment
decreased expression of the corresponding receptors in all cere-
bral areas investigated (P < 0.05) (Fig. 5B).
A dose-dependent influence on RyR expression in aODN
treated animals as well as a correlation between degree of RyR
subtype knockdown and severity of learning retrieval was ob-
served. The dose of 1 nmol per mouse of each aODN did not
significantly reduce the corresponding RyR protein level and was
devoid of any effect on learning processes. The dose of 5 nmol
per mouse reduced protein levels in anti-RyR1 (82.0  6.8, hip-
pocampus), anti-RyR2 (76.7  6.9, cortex; 73.1  7.6 hippocam-
pus), and anti-RyR3 (80.7  6.7, cortex; 78.7  5.8 hippocam-
pus). This dose produced a reduction of the latency to enter the
dark compartment in RyR2 and RyR3 knockdown mice that did
not reach the statistical significance (Fig. 4B,C).
Figure 4. (A) Lack of effect of anti-RyR1 treatment (5–9 nmol per
mouse i.c.v.) in the mouse passive avoidance test. Doses of anti-RyR1
administered (nmol per mouse i.c.v.) are reported in each column. Data
are expressed as mean  SEM; *P < <0.05 in comparison with dODN-
treated mice; (clon) clonidine 0.125 mg/kg i.p. (B) Dose-response curve
of the amnesic effect of anti-RyR2 treatment (1–7 nmol per mouse i.c.v.)
in the mouse passive avoidance test. Doses of anti-RyR2 administered
(nmol per mouse i.c.v.) are reported in each column. Data are expressed
as mean  SEM; *P < 0.05 in comparison with dODN-treated mice;
(clon) clonidine 0.125 mg/kg i.p. (C) Dose-response curve of the amnesic
effect of anti-RyR3 treatment (1–7 nmol per mouse i.c.v.) in the mouse
passive avoidance test. Doses of anti-RyR3 administered (nmol per mouse
i.c.v.) are reported in each column. Data are expressed as mean  SEM;
*P < 0.05 in comparison with dODN-treated mice; (clon) clonidine 0.125
mg/kg i.p.
Figure 3. Reversal by 4-Cmc of the amnesia induced by ryanodine in
the mouse passive avoidance test. Doses administered (nmol per mouse
i.c.v.) are reported below each column. 4-Cmc and ryanodine were in-
jected 30 min before and immediately after the training session, respec-
tively. Data are expressed as mean  SEM; *P < 0.05 in comparison with
saline-treated mice.
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The dODN did not significantly change the immunoreac-
tivity when compared with that of naïve animals. Immunopre-
cipitation experiments also produced similar results (data not
shown).
Immunoblots were reprobed for a protein considered to be
not regulated as -actin, and no significant density difference
was revealed for this protein between samples from the RyR1,
RyR2, and RyR3 downregulated brain region (data not shown).
Cross-reactivity of the primary antibodies used was ex-
cluded.
Time-dependent reversibility of RyR protein
knockdown and memory impairment
To evaluate the reversibility of the aODN effects, mice were
treated with the aODNs on days 1, 2, and 3; 7 d after the last i.c.v.
injection, mice were killed, and the cortex and hippocampus
were dissected and examined for the protein levels of RyR1,
RyR2, and RyR3 in comparison with mice treated with dODN.
Figure 6A shows a representative immunoblot where three dis-
tinct prominent protein bands of ∼500 kDa, corresponding to
RyR1, RyR2, and RyR3, were observed in the mouse hippocampus
and cortex, with the exception of the RyR1 isoform that was not
detected in mouse cortex (Fig. 5A). RyR subtypes protein expres-
sion in aODN treated mice was similar to control animals in both
brain regions.
A time-course of the amnesia obtained after aODN treat-
ment was performed. The impairment of memory processes pro-
duced by anti-RyR2 and anti-RyR3 at the active dose (7 nmol per
mouse i.c.v.) disappeared 7 d after the end of the aODN pretreat-
ment (Fig. 6B). The anti-RyR1 treated group showed entrance
latency values in the retention session comparable to control,
anti-RyR2, and anti-RyR3 treated groups (Fig. 6B).
Effect of RyR pharmacological modulators and aODNs
on mouse behavior
The spontaneous mobility and exploratory activity of mice pre-
treated with anti-RyR1 (9 nmol per mouse i.c.v.), anti-RyR2
(7 nmol per mouse i.c.v.), anti-RyR3 (7 nmol per mouse i.c.v.),
ryanodine (0.1 nmol per mouse i.c.v.), and 4-Cmc (9 nmol per
mouse i.c.v.) was evaluated by using the hole-board test. Both
parameters in all treated groups were not impaired when com-
pared with that of control mice. In the same experimental con-
ditions D-amphetamine (1 mg/kg i.p.), used as the reference
drug, increased both spontaneous mobility (F(6,77) = 4.343;
P < 0.05) and exploratory activity (F(6,77) = 3.998; P < 0.05) (Fig.
7A,B).
The motor coordination of mice was unmodified by admin-
istration of the above-mentioned treatments as revealed by the
rota rod test. The number of falls from the rotating rod was com-
Figure 6. Reversibility of RyR1, RyR2, and RyR3 protein knockdown and
memory impairment in aODN-treated mice in comparison with corre-
sponding dODN-treated mice. (A) Samples (100 µg protein/lane) of mi-
crosomal fractions of mouse cortex and hippocampus were resolved on
6% SDS-PAGE, transferred to nitrocellulose, and probed with RyR1, RyR2,
or RyR3 antibody. (B) Lack of effect of anti-RyR1 (9 nmol per mouse i.c.v.),
anti-RyR2 (7 nmol per mouse i.c.v.), and anti-RyR3 (7 nmol per mouse
i.c.v.) in the mouse passive avoidance test performed 7 d after the end of
the aODN repeated treatment. Data are expressed as mean  SEM;
*P < 0.05 in comparison with the corresponding training session values
(Student’s t-test).
Figure 5. Reduction of RyR1, RyR2, and RyR3 protein expression in
mouse muscle, heart, cortex, and hippocampus by aODN treament in
comparison with corresponding dODN-treated mice. (A) Samples (100
µg protein/lane) of microsomal fractions of mouse cortex and hippocam-
pus, and samples of heart (20 µg protein/lane) and muscle (50 µg pro-
tein/lane) were resolved on 6% SDS-PAGE, transferred to nitrocellulose,
and probed with RyR1, RyR2, or RyR3 antibody. (B) Densitometric quan-
titation of immunoreactive protein expressed relative to control. Data are
expressed as mean  SEM of band intensities from each of the three
groups (n = 7 per group). *P < 0.05 vs. control.
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parable with those of control mice at every session of the test
(Fig. 7C).
Discussion
The role played by the three RyR isoforms in the modulation of
memory processes is illustrated by these results. A different in-
volvement of central RyR subtypes was demonstrated. In particu-
lar, the integrity and functionality of RyR2 and RyR3 proteins
appears essential to avoid memory impairments. By contrast, the
RyR1 subtype, in these experimental conditions, appears not to
be involved.
The effect produced by ryanodine, a RyR pharmacological
antagonist, was investigated in a mouse passive avoidance task.
I.c.v. administration of ryanodine induced amnesia in mice. Neu-
rons with pharmacologically reduced slow afterhyperpolariza-
tion currents (IsAHP) showed facilitated LTP. In particular, in
peripheral neurons, a complete block of IsAHP was reported with
ryanodine (Moore et al. 1998). However, in central neurons the
involvement of RyRs in the reduction of IsAHP appears to be less
evident. The CICR mechanism contributes less to the IsAHP (Kumar
and Foster 2004; Van de Vrede et al. 2007) or does not participate
to generation of IsAHP (Zhang et al. 1995). The ryanodine reten-
tion loss was observed only when the RyR antagonist was admin-
istered immediately after the training session. In accordance with
our data, the RyR antagonist dantrolene produced a retention loss
in chicks in a single trial passive avoidance task when administered
immediately after training (Edwards and Rickard 2006). To confirm
the role of RyRs in a mouse passive avoidance paradigm, the effect
of 4-Cmc, a RyR agonist (Herrmann-Frank and Varsanyi 1993),
was tested. 4-Cmc produced a dose-dependent ameliorating ef-
fect on memory processes demonstrated by an increase of the
latency to enter the dark compartment in the retention session of
the test. Conversely to ryanodine, this effect was obtained
when 4-CmC was administered 30 min before the training test.
This discrepancy can be explained con-
sidering that it has been observed that
the antinociceptive (Galeotti et al.
2004b) and depressant-like (Galeotti
et al. 2006) effects produced by 4-Cmc
became significant starting from 90 min
after administration. Taking into ac-
count this latency to produce its phar-
macological effects, the action of 4-Cmc
on memory processes might appear ap-
proximately in correspondence to the
ryanodine effect. Since both RyR phar-
macological modulators exerted their ef-
fect after the aversive stimulus of the
training session was applied, we might
hypothesize a possible action on re-
trieval rather than on the memory ac-
quisition. However, given that 24 h are
present between learning the task and
recalling the task, any other mechanism
cannot be excluded.
Ryanodine is a selective RyR an-
tagonist unable to distinguish among
RyR subtypes. To investigate the role
played by the RyR isoforms, an antisense
strategy was necessary since mice miss-
ing the RyR1 and RyR2 gene products
die early during embryonic develop-
ment. Mice carrying a targeted disrup-
tion of the RyR1 gene show complete
loss of the skeletal muscle excitation-
contraction coupling and die perinatally because of respiratory
failure (Takeshima et al. 1995). Similar to what observed in RyR1
knockout mice, the generation of mice carrying a targeted dis-
ruption of the RyR2 gene indicates a pivotal role for the RyR2
isoform, not only in cardiac excitation-contraction coupling but
also during myocardial development, as RyR2 knockout mice die
at embryonic day 10 and show morphological abnormalities in
the heart tub (Takeshima et al. 1998). These observations ruled
out the possibility of using RyR1 and RyR2 knockout mice for
behavioral studies. Mice lacking both RyR1 and RyR3 were also
generated. These double-mutant mice did not actively move after
birth and died, most probably from respiratory failure, as was the
case for RyR1-deficient mice (Ikemoto et al. 1997)
RyRs are distributed not only in the central nervous system
but also at a peripheral level. RyRs are present in the skeletal and
cardiac muscle where their activation represents a crucial step for
muscle contraction (Rossi and Sorrentino 2002). To avoid the
possible appearance of peripheral effects that could lead to a
misinterpretation of the results obtained, the aODNs used were
administered directly into the cerebral ventricles.
The capability of the aODN treatment to knock down RyR
protein levels was demonstrated by immunoblotting and immu-
noprecipitation experiments where the levels of RyR1, RyR2, and
RyR3 from microsomes prepared from hippocampus and cortex
of animals treated with the corresponding aODN, in comparison
with the dODN-treated mice, were determined. A selective de-
crease of RyR1, RyR2, and RyR3 protein levels was demonstrated
by using selective antibodies for each RyR isoform.
Knockdown of RyR2 produced memory disruption of inten-
sity comparable to that induced by amnesic drugs such as the
2-adrenoceptor agonist clonidine (Galeotti et al. 2004a) and the
antihistamine diphenhydramine (Galeotti et al. 2003), indicat-
ing the importance of the integrity and functionality of the type
2 RyR isoform for the memory processes in a mouse passive
avoidance task. In agreement with our results, the importance of
Figure 7. Lack of effect of anti-RyR1 (9 nmol per mouse i.c.v.), anti-RyR2 (7 nmol per mouse i.c.v.),
anti-RyR3 (7 nmol per mouse i.c.v.), ryanodine (0.1 nmol per mouse i.c.v.), and 4-Cmc (9 nmol per
mouse i.c.v.) on mouse spontaneous mobility (A) and exploratory activity (B) evaluated in the mouse
hole board test, and on motor coordination (C) evaluated in the rota rod test. ODNs were administered
once daily for 3 d. The test was performed 18 h after the last injection. Amphetamine (amph) was
administered at the dose of 1 mg/kg s.c.; data are expressed as mean  SEM; *P < 0.05 vs. control
group.
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hippocampal microsomal RyR2 isoform in memory functions
was postulated, since RyR2 mRNA and protein levels were up-
regulated in the hippocampus of rats intensely trained in a water
maze (Zhao et al. 2000). Present results confirm and further ex-
tend the knowledge on the crucial role played by RyR2 in the
mnemonic functions.
To date, discrepant results on RyR3 involvement in memory
were obtained by using RyR3 knockout mice. Futatsugi et al.
(1999) noted improved spatial ability of RyR3 deficient mice. By
contrast, Balshun et al. (1999) observed equivalent learning for
both transgenic and wild-type animals. However, the transgenic
mice demonstrated impaired ability to relearn a new target. We
thought it necessary to investigate the RyR3 role by using a dif-
ferent experimental approach. We generated knockdown mice
by using an antisense strategy. RyR3 knockdown animals showed
memory impairment in the passive avoidance test demonstrated
by a reduced latency to enter the dark compartment in the re-
tention session of the test in comparison with the dODN-treated
mice. In the present study, we demonstrated that the function-
ality of type 3 RyR is required for memory processing. In support
to our results, Kouzu et al. (2000) reported that RyR3-deficient
mice exhibited impairments of performance in the contextual
fear conditioning test, passive avoidance test, and Y-maze learn-
ing test further confirming the role of RyR3 in memory func-
tions. The reduction of expression of RyR3 by antisense treat-
ment induced an amnesia of comparable intensity to that ob-
served in anti-RyR2 treated mice and it appeared at the same
concentrations. A similar involvement of these two receptor sub-
types in memory functions in a mouse passive avoidance task can
be postulated.
Conversely to anti-RyR2 and anti-RyR3 treated mice, RyR1
knockdown animals did not show any memory impairment in
comparison with dODN-treated mice. The lack of effect of an
aODN against RyR1 implies that this receptor subtype is not a
major component of transduction mechanisms modulating
memory functions. This observation represents the first investi-
gation on the physiological role of cerebral RyR1. The lack of
effect by the anti-RyR1 aODN in the mouse memory functions as
a consequence to inefficient knockdown of the RyR1 protein by
the antisense treatment can be ruled out. Western blotting and
immunoprecipitation experiments revealed a reduction of the
RyR1 protein levels with the highest dose administered of anti-
RyR1. The different role of the three RyR isoforms in memory
processes might be due the different cerebral distribution of
RyR1, RyR2, and RyR3. Type 2 RyR represents the predominant
isoform in the central nervous system found in widespread brain
regions (McPherson and Campbell 1993; Giannini et al. 1995).
Type 3 RyR has also a wide cerebral distribution including areas
involved in memory processes such as hippocampus and cortex.
Conversely, RyR1 has a limited distribution being absent in the
cortex, as demonstrated by immunoblotting experiments, and in
agreement with literature data (Giannini et al. 1995).
aODNs transiently inactivate single genes down-regulating
the synthesis of the encoded protein. The reversibility of the
aODN effect is fundamental to ensure that the behavioral effects
observed were related to the knockdown of the target protein.
The memory disruption observed in anti-RyR2 and anti-RyR3
treated animals disappeared 7 d after pretreatment with the
aODNs. This return of sensitivity implies both the total reversal
of aODN-induced specific inhibition of RyR proteins and a lack of
damage or toxicity associated with aODN treatment. Time-course
experiments on RyR knockdown mice might also support the
argument that acquisition and/or consolidation processes were
not altered by the treatments given the reversal of the effect with
time.
Pretreatment with aODNs at the highest effective doses did
not modify the entrance latency in the training session, showing
the absence of any unspecific effect produced by these pretreat-
ments. This observation ruled out the possibility that the amne-
sic effect exerted by aODNs may have resulted from a sequence-
independent action on cerebral structures.
As RyRs are widely distributed in the neural areas, the func-
tion of a variety of cellular receptors might be altered by phar-
macological modulators as well as by the impairing effect of the
antisense treatment. It has been, therefore, necessary to evaluate
the possible induction of side effects by ryanodine, 4-Cmc, and
the anti-RyR treatments. All compounds investigated did not
modify animals’ gross behavior. Additional behavioral tests were,
then, performed to unmask any side effect produced by the treat-
ments that cannot be revealed by the researcher through the
observation of the animal’s spontaneous behavior. In the passive
avoidance test, an altered motor activity may shorten the latency
to enter the dark compartment giving a false positive effect. The
treatments did not impair motor coordination, as revealed by the
progressive reduction of the number of falls in the rota rod test.
The number of falls in this test progressively decreases since ani-
mals learn how to balance on the rotating rod. The lack of varia-
tion, or an increase in the number of falls after treatment, indi-
cates an impairment of mice motor coordination that could lead
to a misinterpretation of the results obtained in the behavioral
test. Moreover, treatments did not modify spontaneous mobility
and exploratory activity as indicated by the hole-board test. We
can, thus, suppose that the effects observed in the passive avoid-
ance test were not imputable to compromised behavioral para-
digms. These results were of particular relevance since it has been
observed that deletion of ryanodine receptor type 3 induces an
increased speed of locomotion and a mild tendency to circular
running (Balschun et al. 1999).
In conclusion, our results demonstrate that stimulation of
RyRs ameliorates memory processes whereas a RyR blockade in-
duces amnesia. In particular, knockdown of RyR2 and RyR3 in-
duced a detrimental effect on memory functions indicating their
fundamental role in memory processing. Conversely, RyR1 ap-
pears not to be endowed with a prominent role in the cellular
events involved in learning and memory. Finally, present results
indicate that a gene-specific cerebral RyR isoform level reduction
by using an antisense strategy is compatible with animal life, is
devoid of behavioral side effects, and represents a useful tool to




Male Swiss albino mice (23–30 g) from the Morini (San Polo
d’Enza, Italy) breeding farm were used. Fifteen mice were housed
per cage. The cages were placed in the experimental room 24 h
before the test for acclimatization. The animals were fed a stan-
dard laboratory diet and tap water ad libitum and kept at
23  1°C with a 12 h light/dark cycle, light on at 7 a.m. All
experiments were carried out in accordance with the European
Communities Council Directive of 24 November 1986 (86/609/
EEC) for experimental animal care. All efforts were made to mini-
mize the number of animals used and their suffering.
Intracerebroventricular injection technique
Intracerebroventricular administration was performed under
ether anesthesia, as previously described (Galeotti et al. 2006).
Briefly, during anesthesia, mice were grasped firmly by the loose
skin behind the head. A 0.4-mm external diameter hypodermic
needle attached to a 10-µL syringe was inserted perpendicularly
through the skull and no more than 2 mm into the brain of the
mouse, where 5 µL were then administered. The injection site
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was 1 mm to the right or left from the midpoint on a line drawn
through to the anterior base of the ears. Injections were per-
formed into the right or left ventricle, randomly. To ascertain
that the drugs were administered exactly into the cerebral ven-
tricle, some mice (20%) were injected with 5 µL of diluted 1:10
India ink, and their brains examined macroscopically after sec-
tioning. The accuracy of the injection technique was evaluated,
and the percentage of correct injections was 95.
Passive-avoidance test
The test was performed according to the step-through method
described by Jarvik and Kopp (1967). The apparatus consisted of
a two-compartment acrylic box with a lighted compartment con-
nected to a darkened one by a guillotine door. As soon as the
mouse entered the dark compartment, it received a punishing
electrical shock (0.5 mA, 1 sec). The latency times for entering the
dark compartment were measured in the training test and after
24 h in the retention test. The maximum entry latency allowed
in the training and retention sessions was, respectively, 60 and
180 sec. Between 15 and 22 mice were tested.
Hole-board test
The hole-board test was performed according to Galeotti et al.
(2006). The test consisted of a 40-cm square plane with 16 flush
mounted cylindrical holes (3 cm diameter) distributed four by
four in an equidistant, grid-like manner. Mice were placed on the
center of the board one by one and allowed to move about freely
for a period of 10 min each. Two electric eyes, crossing the plane
from midpoint to midpoint of opposite sides, thus dividing the
plane into four equal quadrants, automatically signaled the
movement of the animal (counts in 5 min) on the surface of the
plane (locomotor activity). Miniature photoelectric cells, in each
of the 16 holes, recorded (counts in 5 min) the exploration of the
holes (exploratory activity) by the mice. Twelve mice per group
were tested.
Rota-rod test
The apparatus consisted of a base platform and a rotating rod
with a diameter of 3 cm and a nonslippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in
length, was divided into 5 equal sections by 6 disks. Thus, up to
five mice were tested simultaneously on the apparatus, with a
rod-rotating speed of 16 revolutions per minute. The integrity of
motor coordination was assessed on the basis of the number of
falls from the rod in 30 s according to Vaught et al. (1985). Those
mice scoring less than three and more than six falls in the pretest
were rejected (20%). The performance time was measured before
(pretest) and 15, 30, and 45 min after the beginning of the test.
Twelve mice per group were tested.
Antisense oligonucleotides
Phosphodiester oligonucleotides (ODNs) protected by terminal
phosphorothioate double substitution (capped ODNs) against
possible exonuclease-mediated degradation were purchased from
Tib-Molbiol (Genoa, Italy). The sequences are the following: anti-
RyR1: 5-T*G*CCCCTGACATGTCC*C*C-3; anti-RyR2: 5-T*T*C
GCCCGCATCAGCC*A*T-3; anti-RyR3: 5-A*G*ATGCTAATTGC
ATC*T*C-3 (* indicates the phosphorothioate residues). A 18-
mer fully degenerated ODN (dODN), 5-N*N*NNNNNNNNNNN
NNN*N*N-3 (where N is G, or C, or A, or T), was used as a control
ODN. ODNs were vehiculated intracellularly by an artificial cat-
ionic lipid (DOTAP, Sigma) to enhance both uptake and stability.
aODNs or dODNs were preincubated at 37°C for 30 min with 13
µM DOTAP and supplied to mice by i.c.v. injection of a 5-µL
solution once daily on days 1, 2, and 3.
Preparation of membranes
Mouse brains were dissected to separate specific areas. Mouse
hippocampus and cortex were homogenized in an homogeniza-
tion buffer containing 25 mM Tris-HCl at pH 7.5, 25 mM NaCl,
5 mM EGTA, 2.5 mM EDTA, 2 mM NaPP, 4 mM PNFF, 1 mM
Na3VO4, 1 mM PMSF, 20 µg/mL leupeptin, 50 µg/mL aprotinin,
0.1% SDS. The homogenate was centrifuged at 9000g for 15 min
at 4°C, and the low-speed pellet was discarded. The microsomal
membranes were obtained from the supernatant of the 9000g
spin by centrifugation at 100,000g for 1 h at 4°C. Microsomes
were resuspended in homogenization buffer and stored at
80°C. Protein concentration of the microsomal fraction was
quantified using a protein assay kit (Bio Rad Laboratories). Skel-
etal muscle microsomes were prepared from the posterior leg of
mice. Cardiac microsomes were prepared from the entire heart,
cleaned from large vessels.
Western blot analysis
Membrane homogenates (100 µg) made from cerebellum, hippo-
campus and cortex regions of control and antisense-treated mice
and membrane homogenates from skeletal and cardiac muscle
were separated on 6% SDS-PAGE and transferred onto nitrocel-
lulose membranes (180 min at 80 V) using standard procedures.
Membranes were blocked in PBST (PBS containing 0.1% Tween)
containing 5% nonfat dry milk for 90 min. Following washings,
blots were incubated overnight at 4°C with specific antibodies
against RyR1, RyR2, or RyR3 (1:3000 dilution), a kind gift of
Professor Sorrentino (University of Siena, Italy). After being
washed with PBS containing 0.1% Tween, the nitrocellulose
membrane was incubated with goat anti-rabbit horseradish per-
oxidase-conjugated secondary antisera (1:10,000) and left for 1 h
at room temperature. Blots were then extensively washed accord-
ing to the manufacturer’s instruction and developed using en-
hanced chemiluminescence detection system (Pierce). Exposi-
tion and developing time used was standardized for all the blots.
Densitometric analysis of scanned images was performed on a
Macintosh iMac computer using the public domain NIH Image
program. Measurements in control samples were assigned a rela-
tive value of 100%.
Immunoprecipitation of RyR1, RyR2, RyR3
Immunoprecipitation was carried out on 1 mL of microsomal
fraction containing 200 µg of proteins by incubation for 2 h at
4°C with 10 µg of specific antibodies against RyR1, RyR2, or
RyR3. All tubes then received 20 µL of 25% (v/v) Protein G-
Agarose (Santa Cruz Biotechnology) and incubated for further 2
h at 4°C. Pellets were collected by centrifugation at 1000g for 5
min at 4°C, washed three times with homogenization buffer.
Pellets were finally resuspended in 40 µL of electrophoresis
sample buffer and boiled for 5 min, and samples were processed
by SDS-PAGE.
Drug administration
The following drugs were used: ryanodine, 4-chloro-m-cresol
(Calbiochem); diphenhydramine hydrochloride, D-ampheta-
mine hydrochloride (De Angeli, Rome, Italy); clonidine hydro-
chloride (Sigma). 4-Chloro-m-cresol (4-Cmc) was dissolved in
0.5% ethanol. All other drugs were dissolved in isotonic (NaCl
0.9%) saline solution. Drug and ODNs concentrations were pre-
pared in such a way that the necessary dose could be adminis-
tered in a volume of 5 µL by i.c.v. injection or 10 mL/kg by
subcutaneous (s.c.) or i.p. administration.
To perform time-course experiments, 4-Cmc was adminis-
tered 15, 30, or 60 min before and immediately after the training
session, and ryanodine was administered 15 min before and im-
mediately after the training session. In ryanodine time-course
experiments, longer latencies from the training session (30, 60
min) were not used, since, conversely to 4-Cmc, it is endowed
with a short lasting effect, as observed in previous behavioral
experiments performed in our laboratory (Galeotti et al. 2004b,
2006). From time-course experiments the ideal time of adminis-
tration of 4-Cmc (30 min before training) and ryanodine (imme-
diately after training) was chosen to perform dose-response
curves. The same administration times were used when 4-Cmc
and ryanodine were coadministered. Clonidine and diphenhy-
dramine, used as reference drugs, were administered, respec-
tively, 70 min before and immediately after the training session.
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ODNs were i.c.v. injected once daily on days 1, 2, and 3. Behav-
ioral tests were performed on day 4, 18 h after the last i.c.v.
injection of ODNs, and on day 11. Brain areas to conduct West-
ern blotting experiments were collected on day 4, 18 h after the
last i.c.v injection and on day 11.
Statistical analysis
All experimental results are given as the mean  SEM. Student’s
t-test or a two-way ANOVA followed by Bonferroni/Dunn post-
hoc test was used for statistical analysis; P-values of less than 0.05
were considered significant.
Acknowledgments
This work was supported by grants from the Ministero
dell’Università e della Ricerca.
References
Balkowiec, A. and Katz, D.M. 2002. Cellular mechanisms regulating
activity-dependent release of native brain-derived neurotrophic
factor from hippocampal neurons. J. Neurosci. 22: 10399–10407.
Balschun, D., Wolfer, D.P., Bertocchini, F., Barone, V., Conti, A.,
Zuschratter, W., Missiaen, L., Lipp, H.-P., Frey, J.U., and Sorrentino,
V. 1999. Deletion of the ryanodine receptor type 3 (RyR3) impairs
forms of synaptic plasticity and spatial learning. EMBO J.
18: 5264–5273.
Breuer, A.C., Bond, M., and Atkinson, M.B. 1992. Fast axonal transport
is modulated by altering trans-axolemmal calcium flux. Cell Calcium
13: 249–262.
Campbell, L.W., Hao, S.Y., Thibault, O., Blalock, E.M., and Landfield,
P.W. 1996. Aging changes in voltage-gated calcium currents in
hippocampal CA1 neurons. J. Neurosci. 16: 6286–6295.
Disterhoft, J.F., Moyer Jr., J.R., and Thompson, L.T. 1994. The calcium
rationale in aging and Alzheimer’s disease. Evidence from an animal
model of normal aging. Ann. N. Y. Acad. Sci. 747: 382–406.
Disterhoft, J.F., Thompson, L.T., Moyer Jr., J.R., and Mogul, D.J. 1996.
Calcium dependent afterhyperpolarization and learning in young
and aging hippocampus. Life Sci. 59: 413–420.
Disterhoft, J.F., Wu, W.W., and Ohno, M. 2004. Biophysical alterations
of hippocampal pyramidal neurons in learning, ageing and
Alzheimer’s disease. Ageing Res. Rev. 3: 383–406.
Edwards, T.M. and Rickard, N.S. 2006. Pharmaco-behavioural evidence
indicating a complex role for ryanodine receptor calcium release
channels in memory processing for a passive avoidance task.
Neurobiol. Learn. Mem. 86: 1–8.
Futatsugi, A., Kato, K., Ogura, H., Li, S.-T., Nagata, E., Kuwajima, G.,
Tanaka, K., Itohara, S., and Mikoshiba, K. 1999. Facilitation of
NMDAR-independent LTP and spatial learning in mutant mice
lacking ryanodine receptor type-3. Neuron 24: 701–713.
Galeotti, N., Bartolini, A., and Ghelardini, C. 2003.
Diphenhydramine-induced amnesia is mediated by Gi-protein
activation. Neuroscience 122: 471–478.
Galeotti, N., Bartolini, A., and Ghelardini, C. 2004a. Alpha-2 agonists
induce amnesia though activation of the Gi-protein signalling
pathway. Neuroscience 126: 451–460.
Galeotti, N., Bartolini, A., and Gheladini, C. 2004b. Role of intracellular
calcium in acute thermal pain perception. Neuropharmacology
47: 935–944.
Galeotti, N., Bartolini, A., and Ghelardini, C. 2006. Blockade of
intracellular calcium release induces an antidepressant-like effect in
the mouse forced swimming test. Neuropharmacology 50: 309–316.
Giannini, G., Conti, A., Mammarella, S., Scrobogna, M., and Sorrentino,
V. 1995. The ryanodine receptor/calcium channel genes are widely
and differentially expressed in murine brain and peripheral tissues. J.
Cell Biol. 128: 893–904.
Gibson, G.E. and Peterson, C. 1987. Calcium and the aging nervous
system. Neurobiol. Aging 8: 329–343.
He, X., Yang, F., Xie, Z., and Lu, B. 2000. Intracellular Ca2+ and
Ca2+/calmodulin-dependent kinase II mediate acute potentiation of
neurotransmitter release by neurotrophin-3. J. Cell Biol.
149: 783–792.
Hemond, P. and Jaffe, D.B. 2005. Caloric restriction prevents
aging-associated changes in spike-mediated Ca2+ accumulation and
the slow afterhyperpolarization in hippocampal CA1 pyramidal
neurons. Neuroscience 135: 413–420.
Herrmann-Frank, A. and Varsanyi, M. 1993. Enhancement of Ca2+
release channel activity by phosphorylation of the skeletal muscle
ryanodine receptor. FEBS Lett. 332: 237–242.
Ikemoto, T., Komazaki, S., Takeshima, H., Nishi, M., Noda, T., Iino, M.,
and Endo, M. 1997. Functional and morphological features of
skeletal muscle from mutant mice lacking both type 1 and 3
ryanodine receptors. J. Physiol. 501: 305–312.
Jarvik, M. and Kopp, R. 1967. An improved passive avoidance learning
situation. Psychol. Rep. 21: 221–224.
Kawai, T. and Watanabe, M. 1989. Effects of ryanodine on spike
after-hyperpolarisation in sympathetic neurons of the rat superior
cervical ganglion. Pflug. Arch. Eur. J. Physiol. 413: 470–475.
Khachaturian, Z.S. 1989. The role of calcium regulation in brain aging:
Reexamination of a hypothesis. Aging (Milano) 1: 17–34.
Kouzu, Y., Moriya, T., Takeshima, H., Yoshioka, T., and Shibata, S. 2000.
Mutant mice lacking ryanodine receptor type 3 exhibit deficits of
contextual fear conditioning and activation of
calcium/calmodulin-dependent protein kinase II in the
hippocampus. Brain Res. Mol. Brain Res. 76: 142–150.
Kumar, A. and Foster, T.C. 2004. Enhanced long-term potentiation
during aging is masked by processes involving intracellular calcium
stores. J. Neurophysiol. 91: 2437–2444.
Landfield, P.W. 1987. ‘Increased calcium-current’ hypothesis of brain
aging. Neurobiol. Aging 8: 346–347.
Landfield, P.W. 1996. Aging-related increase in hippocampal calcium
channels. Life Sci. 59: 399–404.
Landfield, P.W. and Pitler, T.A. 1984. Prolonged Ca-dependent
afterhyperpolarizations in hippocampal neurons of aged rats. Science
226: 1089–1092.
Landfield, P.W., Pitler, T.A., and Applegate, M.D. 1986. The effects of
high Mg to-Ca2+ ratios on frequency potentiation in hippocampal
slices of young and aged rats. J. Neurophysiol. 56: 797–811.
McPherson, P.S. and Campbell, K.P. 1993. The ryanodine receptor/Ca2+
release channel. J. Biol. Chem. 19: 13765–13768.
Moore, K.A., Cohen, A.S., Kao, J.P.Y., and Weinrerich, D. 1998.
Ca2+-induced Ca2+ release mediates a slow post-spike
hyperpolarization in rabbit vagal afferent neurons. J. Neurophysiol.
79: 688–694.
Mothet, J.-P., Fossier, P., Meunier, F.-M., Stinnakre, J., Tauc, L., and
Baux, G. 1998. Cyclic ADP-ribose and calcium-induced calcium
release regulate neurotransmitter release at a cholinergic synapse of
Aplysia. J. Physiol. 507: 405–414.
Moyer Jr., J.R., Thompson, L.T., Black, J.P., and Disterhoft, J.F. 1992.
Nimodipine increases excitability of rabbit CA1 pyramidal neurons
in an age- and concentration-dependent manner. J. Neurophysiol.
68: 2100–2109.
Nishiyama, M., Hong, K., Mikoshiba, K., Poo, M.M., and Kato, K. 2000.
Calcium stores regulate the polarity and input specificity of synaptic
modification. Nature 408: 584–588.
Paschen, W., Doutheil, J., Gissel, C., and Treiman, M. 1996. Depletion
of neuronal endoplasmic reticulum calcium stores by thapsigargin:
Effect on protein synthesis. J. Neurochem. 67: 1735–1743.
Pitler, T.A. and Landfield, P.W. 1990. Aging-related prolongation of
calcium spike duration in rat hippocampal slice neurons. Brain Res.
508: 1–6.
Potier, B., Rascol, O., Jazat, F., Lamour, Y., and Dutar, P. 1992.
Alterations in the properties of hippocampal pyramidal neurons in
the aged rat. Neuroscience 48: 793–806.
Rossi, D. and Sorrentino, V. 2002. Molecular genetics of ryanodine
receptors Ca2+-release channels. Cell Calcium 32: 307–319.
Sharp, A.H., McPherson, P.S., Dawson, T.D., Aoki, C., Campbell, K.P.,
and Snyder, S.H. 1993. Differential immunohistochemical
localization of inositol 1,4,5-trisphosphate- and ryanodine-sensitive
Ca2+ release channels in rat brain. J. Neurosci. 13: 3051–3063.
Simpson, P.B., Challiss, R.A.J., and Nahorski, S.R. 1995. Neuronal
calcium stores: Activation and function. Trends Neurosci.
18: 299–305.
Stutzmann, G.E., Smith, I., Caccamo, A., Oddo, S., Laferla, F.M., and
Parker, I. 2006. Enhanced ryanodine receptor recruitment
contributes to Ca2+ disruptions in young, adult, and aged
Alzheimer’s disease mice. J. Neurosci. 26: 5180–5189.
Takeshima, H., Yamazawa, T., Ikemoto, T., Takekura, H., Nishi, M.,
Noda, T., and Iino, M. 1995. Ca2+-induce Ca2+ release in myocytes
from dyspedic mice lacking the type-1 ryanodine receptors. EMBO J.
14: 2999–3006.
Takeshima, H., Komazaki, S., Hirose, K., Nishi, M., Noda, T., and Iino,
M. 1998. Embryonic lethality and abnormal cardiac myocytes in
mice lacking ryanodine receptor type 2. EMBO J. 17: 3309–3316.
Thibault, O., Porter, N.M., Chen, K.C., Blalock, E.M., Kaminker, P.G.,
Clodfelter, G.V., Brewer, L.D., and Landfield, P.W. 1998. Calcium
dysregulation in neuronal aging and Alzheimer’s disease: History
and new directions. Cell Calcium 24: 417–433.
Thibault, O., Hadley, R., and Landfield, P.W. 2001. Elevated
postsynaptic [Ca2+] i and L-type calcium channel activity in aged
hippocampal neurons: Relationship to impaired synaptic plasticity.
J. Neurosci. 21: 9744–9756.
RyR isoforms and memory
322www.learnmem.org Learning & Memory
Toescu, E.C. and Verkhratsky, A. 2003. Neuronal ageing from an
intraneuronal perspective: roles of endoplasmic reticulum and
mitochondria. Cell Calcium 34: 311–323.
Tully, K. and Treistman, S.N. 2004. Distinct intracellular calcium profiles
following influx through N- versus L-type calcium channels: Role of
Ca2+-induce Ca2+ release. J. Neurophysiol. 92: 135–143.
Van de Vrede, Y., Fossier, P., Baux, G., Joels, M., and Chameau, P. 2007.
Control of IsAHP in mouse hippocampus CA1 pyramidal neurons by
RyR3-mediated calcium-induced calcium release. Pflug. Arch. Eur. J.
Physiol. 455: 297–308.
Vaught, J., Pelley, K., Costa, L.G., Sether, P., and Enna, S.J. 1985. A
comparison of the antinociceptive responses to GABA-receptor
agonists THIP and baclofen. Neuropharmacology 24: 211–216.
Zalk, R., Lehnart, S.E., and Mark, A.R. 2007. Modulation of the
ryanodine receptor and intracellular calcium. Annu. Rev. Biochem.
76: 367–385.
Zhang, L., Pennefather, P., Velumian, A., Tymianski, M., Charlton, M.,
and Carlen, P.L. 1995. Potentiation of a slow Ca2+-dependent K+
current by intracellular Ca2+ chelators in hippocampal CA1 neurons
of rat brain slices. J. Neurophysiol. 74: 2225–2241.
Zhao, W., Meiri, N., Xu, H., Cavallaro, S., Quattrone, A., Zhang, L., and
Alkon, D.L. 2000. Spatial learning induced changes in expression of
the ryanodine type II receptor in the rat hippocampus. FASEB J.
14: 290–300.
Received January 25, 2008; accepted in revised form March 3, 2008.
RyR isoforms and memory
323www.learnmem.org Learning & Memory
